De ACM onderzoekt of farmaceut Biogen zich schuldig maakt aan machtsmisbruik
De ACM onderzoekt of farmaceut Biogen zich schuldig maakt aan machtsmisbruik
De Autoriteit Consument & Markt (ACM) onderzoekt of farmaceut Biogen ten onrechte aan koppelverkoop doet.
www.nrc.nl
November 6, 2026 at 2:06 PM
De ACM onderzoekt of farmaceut Biogen zich schuldig maakt aan machtsmisbruik
Dutch antitrust regulators probe Biogen over test for its MS drug.. statnews.com/pharmalot/20... #pharma #antitrust #competition #Netherlands #Biogen #multiplesclerosis #MS
Dutch antitrust regulators probe Biogen over test for its MS drug
Dutch anti-trust regulators are investigating allegations that Biogen may have abused its dominant position in the market for MS treatments and associated blood tests.
statnews.com
November 10, 2026 at 2:02 PM
Dutch antitrust regulators probe Biogen over test for its MS drug.. statnews.com/pharmalot/20... #pharma #antitrust #competition #Netherlands #Biogen #multiplesclerosis #MS
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
STAT News
https://www.statnews.com/pharmalot/2026/11/10/dutch-antitrust-regulators-probe-biogen-over-multiple-sclerosis-drug-test/?utm_campaign=rss
STAT News
https://www.statnews.com/pharmalot/2026/11/10/dutch-antitrust-regulators-probe-biogen-over-multiple-sclerosis-drug-test/?utm_campaign=rss
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
STAT News
www.statnews.com
November 10, 2026 at 1:51 PM
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
STAT News
https://www.statnews.com/pharmalot/2026/11/10/dutch-antitrust-regulators-probe-biogen-over-multiple-sclerosis-drug-test/?utm_campaign=rss
STAT News
https://www.statnews.com/pharmalot/2026/11/10/dutch-antitrust-regulators-probe-biogen-over-multiple-sclerosis-drug-test/?utm_campaign=rss
Piper Sandler Raises Biogen Price Target to $305 From $245
November 9, 2026 at 4:29 AM
Piper Sandler Raises Biogen Price Target to $305 From $245
Piper Sandler Raises Biogen Price Target to $305 From $245
November 9, 2026 at 4:29 AM
Piper Sandler Raises Biogen Price Target to $305 From $245
ACM onderzoekt mogelijk misbruik machtspositie door Biogen
ACM onderzoekt mogelijk misbruik machtspositie door Biogen
De ACM onderzoekt of Biogen concurrentie belemmert door een bloedtest voor MS-patiënten alleen beschikbaar te stellen bij behandeling met Tysabri.
nieuws.nl
November 6, 2026 at 12:11 PM
ACM onderzoekt mogelijk misbruik machtspositie door Biogen
Watching $BIIB and Biogen: diranersen ASO reduces MAPT mRNA; CSF p-tau + tau PET are focus/exposure. If 96wk concordance I call +30% rerate. https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-data-across-alzheimers-disease-portfolio-ctad
November 7, 2026 at 9:06 PM
Watching $BIIB and Biogen: diranersen ASO reduces MAPT mRNA; CSF p-tau + tau PET are focus/exposure. If 96wk concordance I call +30% rerate. https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-data-across-alzheimers-disease-portfolio-ctad
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
Dutch anti-trust regulators are investigating allegations that Biogen may have abused its dominant position in the market for multiple sclerosis treatments and associated blood tests. The Netherlands Authority for Consumers…
Dutch anti-trust regulators are investigating allegations that Biogen may have abused its dominant position in the market for multiple sclerosis treatments and associated blood tests. The Netherlands Authority for Consumers…
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
Dutch anti-trust regulators are investigating allegations that Biogen may have abused its dominant position in the market for multiple sclerosis treatments and associated blood tests. The Netherlands Authority for Consumers and Markets, also known by its Dutch acronym ACM, is probing whether the company reserved a test for patients who are treated with Tysabri, its MS drug, and refusing to make the test available to patients on rival medications, such as Tyruko, a biosimilar version that is sold by Sandoz.
jbiznews.com
November 10, 2026 at 1:58 PM
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
Dutch anti-trust regulators are investigating allegations that Biogen may have abused its dominant position in the market for multiple sclerosis treatments and associated blood tests. The Netherlands Authority for Consumers…
Dutch anti-trust regulators are investigating allegations that Biogen may have abused its dominant position in the market for multiple sclerosis treatments and associated blood tests. The Netherlands Authority for Consumers…
#SUPN Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
https://www.stocktitan.net/news/SUPN/biogen-provides-update-on-private-payer-coverage-for-zurzuvaetm-5q9miyll0rcf.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/SUPN/biogen-provides-update-on-private-payer-coverage-for-zurzuvaetm-5q9miyll0rcf.html?utm_source=stocktitan-bluesky&utm_medium=social
Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
Biogen Canada announced that most national private drug plans now cover ZURZUVAE for eligible Canadian adults with postpartum depression.The coverage concerns treatment of moderate or severe postpartum depression following childbirth. Reimbursement remains subject to individual plan eligibility and requirements, which vary by plan and insurer. Biogen Canada works with insurers, employers and healthcare professionals to support access and offers additional services through a patient support program.
www.stocktitan.net
November 5, 2026 at 4:00 PM
#SUPN Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
https://www.stocktitan.net/news/SUPN/biogen-provides-update-on-private-payer-coverage-for-zurzuvaetm-5q9miyll0rcf.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/SUPN/biogen-provides-update-on-private-payer-coverage-for-zurzuvaetm-5q9miyll0rcf.html?utm_source=stocktitan-bluesky&utm_medium=social
Ex-PI: Biogen and $BIIB run a MAPT ASO. Robust MAPT mRNA knockdown should lower CSF p-tau and tau PET; 96-week biomarker concordance will rerate the stock. Focus, exposure, perspectve. https://longevity.technology/news/biogens-tau-drug-diranersen-gets-a-ctad-spotlight/
November 10, 2026 at 3:04 PM
Ex-PI: Biogen and $BIIB run a MAPT ASO. Robust MAPT mRNA knockdown should lower CSF p-tau and tau PET; 96-week biomarker concordance will rerate the stock. Focus, exposure, perspectve. https://longevity.technology/news/biogens-tau-drug-diranersen-gets-a-ctad-spotlight/
Books I've Read - The Dictionary of Lost Words by #PipWilliams https://kensbookinfo.blogspot.com/p/books-ive-read.html#5626452
Netherlands: Watchdog probes #US drugmaker #Biogen over restricted access to multiple sclerosis test - https://kensbookinfo.blogspot.com/p/etc.html#Netherlands
Netherlands: Watchdog probes #US drugmaker #Biogen over restricted access to multiple sclerosis test - https://kensbookinfo.blogspot.com/p/etc.html#Netherlands
November 7, 2026 at 8:04 PM
Books I've Read - The Dictionary of Lost Words by #PipWilliams https://kensbookinfo.blogspot.com/p/books-ive-read.html#5626452
Netherlands: Watchdog probes #US drugmaker #Biogen over restricted access to multiple sclerosis test - https://kensbookinfo.blogspot.com/p/etc.html#Netherlands
Netherlands: Watchdog probes #US drugmaker #Biogen over restricted access to multiple sclerosis test - https://kensbookinfo.blogspot.com/p/etc.html#Netherlands
JPMorgan raised its Swedbank price target to SEK 401. Piper Sandler increased targets for Biogen and Moderna to $305. BHP and GoMount signed a copper cathode memorandum. An Iraqi gas complex drone attack caused power outages. Japan will fund regional bank cybersecurity.
November 9, 2026 at 4:43 AM
JPMorgan raised its Swedbank price target to SEK 401. Piper Sandler increased targets for Biogen and Moderna to $305. BHP and GoMount signed a copper cathode memorandum. An Iraqi gas complex drone attack caused power outages. Japan will fund regional bank cybersecurity.
This episode of The Expert Series was sponsored by Biogen. The Lupus Foundation of America would like to thank Biogen for their support of education programs for people with lupus.
November 2, 2026 at 9:02 PM
This episode of The Expert Series was sponsored by Biogen. The Lupus Foundation of America would like to thank Biogen for their support of education programs for people with lupus.
I've been watching $BIIB. Biogen pairs tau antisense diranersen with Abeta/C3, sharpens focus on overlap. If 76-96wk biomarkers align I call +45% rerate. pharmacokinetcs analysi. https://finance.yahoo.com/healthcare/articles/biogen-present-data-across-alzheimers-105900437.html
November 4, 2026 at 3:05 PM
I've been watching $BIIB. Biogen pairs tau antisense diranersen with Abeta/C3, sharpens focus on overlap. If 76-96wk biomarkers align I call +45% rerate. pharmacokinetcs analysi. https://finance.yahoo.com/healthcare/articles/biogen-present-data-across-alzheimers-105900437.html
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more news.. statnews.com/pharmalot/20... #pharma #eyes #antitrust #medicines #biotech #peptide #stroke #Ebola #China #Bayer #Merck #Lilly #NovoNordisk #Biogen
Pharmalittle: We're reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more
The FDA approved a novel drug to reduce recurrence of stroke, the agency is warning that GLP-1s carry a potential risk for an eye condition, and more pharma news of the day.
statnews.com
November 10, 2026 at 2:30 PM
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more news.. statnews.com/pharmalot/20... #pharma #eyes #antitrust #medicines #biotech #peptide #stroke #Ebola #China #Bayer #Merck #Lilly #NovoNordisk #Biogen
Cutaneous Lupus Erythematosus Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and ROA Trends | Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen
https://www.pressreleasecc.com/2026/11/03/cutaneous-lupus-erythematosus-pipeline-analysis-2026-phase-iii-and-phase-ii-assets-moa-breakdown-and-roa-trends-biogen-horizon-therapeutics-bristol-myers-squibb-astrazeneca-sanofi-am-2
www.pressreleasecc.com
November 5, 2026 at 3:12 AM
Cutaneous Lupus Erythematosus Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and ROA Trends | Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen
【タウ標的薬の96週データと、レカネマブの5年追跡を発表】
Biogenが、CTAD 2026でアルツハイマー病領域の新データを発表する。タウ標的のdiranersen（BIIB080）は第2相CELIA試験の96週長期延長データを出す。lecanemabはClarity AD非盲検延長の5年間データと、LEADER試験の3年間実臨床データを示す。Biogen、CTAD2026でアルツハイマー病領域の新データを発表──タウ標的diranersenは第2相で96週延長データ、レカネマブは5年間の長期追跡データを公表
stellanews.life/technology/1...
Biogenが、CTAD 2026でアルツハイマー病領域の新データを発表する。タウ標的のdiranersen（BIIB080）は第2相CELIA試験の96週長期延長データを出す。lecanemabはClarity AD非盲検延長の5年間データと、LEADER試験の3年間実臨床データを示す。Biogen、CTAD2026でアルツハイマー病領域の新データを発表──タウ標的diranersenは第2相で96週延長データ、レカネマブは5年間の長期追跡データを公表
stellanews.life/technology/1...
Biogen、CTAD2026でアルツハイマー病領域の新データを発表──タウ標的diranersenは第2相で96週延長データ、レカネマブは5年間の長期追跡データを公表
Biogen社は2026年11月のCTAD会議で、タウ標的の開発中薬剤diranersenの第2相CELIA試験に関する96週長期延長データと、lecanemab（レカネマブ）の5年間長期追跡・実臨床データを発表する。
stellanews.life
November 6, 2026 at 8:38 AM
【タウ標的薬の96週データと、レカネマブの5年追跡を発表】
Biogenが、CTAD 2026でアルツハイマー病領域の新データを発表する。タウ標的のdiranersen（BIIB080）は第2相CELIA試験の96週長期延長データを出す。lecanemabはClarity AD非盲検延長の5年間データと、LEADER試験の3年間実臨床データを示す。Biogen、CTAD2026でアルツハイマー病領域の新データを発表──タウ標的diranersenは第2相で96週延長データ、レカネマブは5年間の長期追跡データを公表
stellanews.life/technology/1...
Biogenが、CTAD 2026でアルツハイマー病領域の新データを発表する。タウ標的のdiranersen（BIIB080）は第2相CELIA試験の96週長期延長データを出す。lecanemabはClarity AD非盲検延長の5年間データと、LEADER試験の3年間実臨床データを示す。Biogen、CTAD2026でアルツハイマー病領域の新データを発表──タウ標的diranersenは第2相で96週延長データ、レカネマブは5年間の長期追跡データを公表
stellanews.life/technology/1...
Khader (Biogen), "In neurologia diagnosi precoce leva strategica per l'innovazione"
https://vivere.me/hgpp-k
Khader (Biogen), "In neurologia diagnosi precoce leva strategica per l'innovazione"
vivere.me
November 2, 2026 at 2:35 PM
Khader (Biogen), "In neurologia diagnosi precoce leva strategica per l'innovazione"
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
lamilano.it
November 2, 2026 at 2:26 PM
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
(Biogen), "In neurologia diagnosi precoce leva strategica per l'innovazione"
https://vivere.me/hgm2-k
(Biogen), "In neurologia diagnosi precoce leva strategica per l'innovazione"
vivere.me
November 2, 2026 at 12:07 PM
(Biogen), "In neurologia diagnosi precoce leva strategica per l'innovazione"
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
lamilano.it
November 2, 2026 at 2:26 PM
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
Khader (Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
(Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”
(Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
(Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
(Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”
(Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
lamilano.it
November 2, 2026 at 11:26 AM
(Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”
(Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".
(Biogen), “In neurologia diagnosi precoce leva strategica per l’innovazione”. "La diagnosi precoce rappresenta oggi una priorità per il sistema salute".